Currently, CDK4/6i are the standard-of-care therapy in combination with endocrine therapy (ET) in patients with HR+, human epidermal growth factor receptor 2 (HER2)-negative metastatic BC [15]. The gene discussed is ERBB2; the disease is breast cancer.